Chiesi Farmaceutici S.p.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chiesi Farmaceutici S.p.A.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cornerstone Therapeutics (Cardiokine, Inc.
- Critical Therapeutics, Inc.
- EKR Therapeutics Inc.)
- Torrex Chiesi Pharma
- Zymenex Holding A/S
- Atopix Therapeutics Limited